Wall Street analysts expect Zafgen Inc (NASDAQ:ZFGN) to report ($0.45) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Zafgen’s earnings, with estimates ranging from ($0.46) to ($0.43). Zafgen reported earnings of ($0.46) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.2%. The firm is expected to issue its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Zafgen will report full year earnings of ($2.05) per share for the current financial year, with EPS estimates ranging from ($2.09) to ($1.99). For the next year, analysts forecast that the business will post earnings of ($1.95) per share, with EPS estimates ranging from ($2.22) to ($1.81). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02.
Shares of Zafgen stock opened at $10.25 on Tuesday. Zafgen has a 52-week low of $3.37 and a 52-week high of $12.35. The company has a market capitalization of $430.25 million, a P/E ratio of -5.39 and a beta of -0.64. The company has a current ratio of 8.42, a quick ratio of 8.42 and a debt-to-equity ratio of 0.36.
Several large investors have recently bought and sold shares of the business. A.R.T. Advisors LLC increased its position in shares of Zafgen by 62.9% during the 1st quarter. A.R.T. Advisors LLC now owns 23,053 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 8,904 shares during the last quarter. Granahan Investment Management Inc. MA increased its position in shares of Zafgen by 15.8% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 69,647 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 9,503 shares during the last quarter. Voya Investment Management LLC acquired a new position in shares of Zafgen during the 2nd quarter worth approximately $104,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Zafgen during the 2nd quarter worth approximately $110,000. Finally, Trexquant Investment LP acquired a new position in shares of Zafgen during the 2nd quarter worth approximately $117,000. 72.58% of the stock is currently owned by hedge funds and other institutional investors.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.